Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches
04:47am, Saturday, 18'th Oct 2025
Neurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline. NBIX's Q2 2025 revenue reached $682 million, with INGREZZA c
Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
04:01pm, Tuesday, 07'th Oct 2025
Conference Call and Webcast Scheduled for Tuesday, October 28 SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quart
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
04:05pm, Monday, 06'th Oct 2025
SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neurop
Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease a
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 24'th Sep 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KI
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
08:30am, Monday, 22'nd Sep 2025
SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically sign
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
04:13pm, Wednesday, 17'th Sep 2025
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT Company Participants Kyle Gano - CEO & Director
Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO , Sept. 16, 2025 /PRN
Neurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
01:37pm, Tuesday, 09'th Sep 2025
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chie
Neurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 Transcript
03:20pm, Wednesday, 03'rd Sep 2025
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chie
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
04:01pm, Tuesday, 26'th Aug 2025
SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commerci
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 20'th Aug 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang f
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
04:01pm, Wednesday, 06'th Aug 2025
SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 20
